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 Perinatal psychiatric illness is a known complication of pregnancy and childbirth.  Risk 
factors for Perinatal Mood and Anxiety Disorders (PMAD) are well established, and validated 
screening questionnaires to assess risk factors and symptoms are readily available.  Several 
national governing bodies recommend screening women for pregnancy and postpartum mood 
disorders; however, these recommendations do not designate which screening questionnaires to 
use, when to administer the questionnaires, or how to proceed after screening assessment.  This 
paper outlines the background of PMAD, screening recommendations, and the design of a 
quality improvement project aimed at implementing a PMAD screening protocol at Lawrence 
OB-GYN Specialists, a women’s health care clinic at LMH Health in Lawrence, Kansas.  The 
Ottawa Model of Research Use guided the project (National Collaborating Center for Methods 
and Tools, 2017).  A pre-protocol survey assessed the clinic environment, including screening 
practices, as well as opinions and knowledge about PMAD.  The screening protocol 
implemented at the 16-week prenatal appointment included the Edinburgh Postnatal Depression 
Scale (EPDS), the Antenatal Risk Questionnaire (ANRQ), a clinical pathway, a resource and 
referral list, and written patient education.  A post-protocol survey assessed the opinions of clinic 
staff regarding the usefulness of the protocol.  Outcomes were measured by survey responses and 
screening questionnaire data.  Information obtained from this project will assist obstetrical 
offices in screening, identifying, and referring pregnant women at risk for perinatal mental 
illness.  
Keywords: Perinatal mood anxiety disorders, maternal mental health, perinatal psychiatric 
illness, peripartum psychiatric illness, Edinburgh Postnatal Depression Scale, Antenatal Risk 
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 This paper outlines the results of a DNP project aimed at increasing the identification of 
women at risk for perinatal mental health complications, thus increasing the likelihood of 
intervention and treatment.  The driving force behind this project was a need for effective care.  
The Institute of Medicine (2001) defines effectiveness as “care that is based on the use of 
systemically acquired evidence to determine whether an intervention, such as a preventive 
service, diagnostic test, or therapy produces better outcomes than alternatives- including the 
alternative of doing nothing” (p. 46).  Diagnostic criteria for perinatal mood disorders and the 
factors that increase the likelihood of perinatal psychiatric illness are well-established.  
Professional organizations governing obstetric, family practice, and pediatric care recognize the 
need to assess perinatal women for mental health complications.  However, despite general 
knowledge, a gap exists between the recommendation and clinical practice.  Clear and consistent 
guidelines for screening, including the timing of screening and use of screening questionnaires, 
are not consistent.  Therefore, screening for perinatal psychiatric illness remains inconsistent, 
hindering identification of women in need of further psychiatric assessment.   
Background and Significance of the Problem 
 Psychiatric illness in the perinatal period takes many forms.  Pregnant and postpartum 
women are at risk for a range of disorders, including Major Depressive Disorder, Generalized 
Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, Bipolar 
Disorder, and Psychosis.  Major depressive disorder is most common followed by generalized 
anxiety disorder, often these disorders occur comorbid (Wisner et al., 2013).  Growing research 
demonstrates the perinatal period as a high-risk time for bipolar relapse or presentation 
(Thomson & Sharma, 2017). 
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 The criteria outlined for these disorders in the Diagnostic and Statistical Manual of 
Mental Disorders- 5 (2013) match the criteria of mood disorders that occur across the lifespan.  
The specifier “with peripartum onset” applies to the onset of symptoms of depressive disorders 
in pregnancy or within 4 weeks postpartum (American Psychiatric Association, 2013, p. 111).  
This specifier applies to major depressive, manic, or hypomanic symptoms beginning in this 
timeframe.  Inconsistency among definitions of the perinatal and postpartum periods in other 
sources vary, causing confusion.  The ICD-10 defined postpartum as the six weeks following 
birth (Stowe, Hostetter, & Newport, 2005).  The American College of Obstetricians and 
Gynecologists ([ACOG], 2015) defined perinatal depression as “major and minor depressive 
episodes that occur during pregnancy or the first twelve months after delivery” (p.1-2).  In 
practice, a majority of clinicians accept the ACOG definition and consider “postpartum” to 
include the 12 months following birth for the purposes of identifying mood disorders in this time 
period.  Consensus regarding the definition would be helpful in identifying and diagnosing 
women with perinatal mood and anxiety disorders.  
 According to the Centers for Disease Control and Prevention (2016), 1 in 9 women will 
experience depression before, after, or during pregnancy.  ACOG (2015) stated one in seven 
women will experience a perinatal episode of depression.  The World Health Organization stated 
10% of pregnant women and 13% of postpartum women will experience a mental disorder, 
especially depression (2018).  Postpartum Support International (n.d.) reported 6% of pregnant 
and 10% of postpartum women will experience significant anxiety.  Additionally, 38% of 
women of color experience perinatal emotional complications, which is twice the rate of White 
women (Keefe, Brownstein-Evans, & Polmanteer, 2016).  Numerous studies document the 
prevalence of this common complication of childbirth.  These studies have shown the postpartum 
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period represents the most common time for psychiatric hospital admission among women 
(Doucet, Dennis, Letourneau, & Blackmore, 2009).  A portion of women enter the childbearing 
years with a history of or current mental illness, including a previous episode of perinatal 
depression, which increases the risk for perinatal psychiatric illness.  Kendig et al. (2017) stated, 
"for women who are diagnosed with postpartum depression, 27% enter pregnancy with a mental 
health disorder, another 33% have onset in pregnancy, and 40% have postpartum onset."   
Additionally, some research suggests women underreport mental health symptoms, raising the 
possibility that the incidence of perinatal mental health complications is even more prevalent.  
Barriers such as stigma and fear may influence a woman’s reporting of psychiatric symptoms.  
Healthcare providers must recognize the opportunities to identify women at risk for or suffering 
from perinatal mood disorders.  
 Maternal mental illness poses a risk not only for the woman, but also for the growing 
fetus or infant, and the family as a whole.  Kendig et al. (2017) stated,  
 When left untreated, perinatal mood and anxiety disorders can have profound adverse 
effects on women and their children, ranging from increased risk of poor adherence to medical 
care, exacerbation of medical conditions, loss of interpersonal and financial resources, smoking 
and substance use, suicide, and infanticide. (p. 232)   
Pregnancy depression potentially creates physiological changes in the mother leading to changes 
in the fetal environment, resulting in complications such as low fetal weight, low birth weight, 
and preterm birth.  In addition to the risks associated with low weight and preterm birth, 
newborns of depressed mothers show biochemical evidence of stress, such as decreased vagal 
tone, higher cortisol levels, and lower dopamine and serotonin levels (Field, Diego, & 
Hernandez-Rief, 2006).  In addition to well-established concerns about maternal and infant 
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bonding after birth, maternal depression may impact parenting practices, such as feeding, 
sleeping, home and car safety, well-child visit attendance, and vaccinations (Field, 2010).  A 
report by the Fetal Infant Mortality Review Program (Shaefer & Abdulahi, 2016) recognizes 
maternal mental health interventions as a community action item to reduce infant mortality.  
Identifying and intervening with women at risk for perinatal psychiatric illness is a proactive step 
in reducing the incidence of maternal and infant health complications.  Assessing risk factors 
prenatally identifies women at risk for peripartum depression, allowing timely assessment and 
intervention. 
Overview of Literature Search Strategy 
 A review of the literature was conducted.  PubMed, CINAHL, Cochrane Library, 
PsycINFO, Psychology and Behavioral Sciences Collection, and Up to Date were searched for 
relevant evidence-based research on this topic.  Concept terms for the topics of interest included 
the population: "expectant mothers, antepartum women, antenatal women, pregnant women, and 
obstetrical patients," the intervention: "EPDS, Edinburgh Postnatal Depression Scale, Antenatal 
Risk Assessment, ANRQ, questionnaire, tool, and assessment," and the outcome: "Perinatal 
mood disorder, maternal mental health, maternal psychiatric illness, perinatal mood and anxiety 
disorder, perinatal psychiatric illness, perinatal depression, postpartum depression, postnatal 
depression, postpartum."  Publications unavailable in English were excluded.  The following 
categories were found among the evidence-based literature reviewed.  Numerous studies reported 
psychosocial factors associated with an increased chance for developing pregnancy or 
postpartum mood disorders.  Validated screening questionnaires exist to assess these risk factors 
and symptoms of perinatal mood disorders, yet there are no clear-cut guidelines regarding how 
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and when to screen for psychosocial indicators or symptoms of this common childbirth 
complication.  
Review of the Literature 
Risk factors for PMAD 
 The risk factors associated with perinatal mood disorders are well established in the 
literature.  Several common factors have been found to correlate with a higher incidence of 
prenatal or postpartum depression.  Howard, Mehta, and Powrie (2017) listed the following: 
“past episodes of depression, current anxiety, poor social support, unintended pregnancy, life 
stress, being single, domestic violence, and being on Medicaid” (p.389) as factors for pregnancy 
depression.  According to Massachusetts General Hospital (MGH) Center for Women's Mental 
Health (2015), a personal or family history of mental illness, increases a woman’s risk of 
perinatal psychiatric illness.  A previous episode of postpartum depression, depression in 
pregnancy, history of depression or bipolar disorder, recent stressful life events, inadequate 
social support, and marital problems are known to increase the risk of perinatal depression.  
Meltzer-Brody et al. (2013) found younger age, greater education (measured in years), higher 
neuroticism, childhood trauma, and sexual abuse after age 16 were to be significant independent 
risk factors for perinatal depression.  Lancaster et al. (2010) reached similar results correlating 
antenatal depression with previous depression or anxiety, life stress, lack of social support, 
domestic violence, unplanned pregnancy, and Medicaid use. Screening questionnaires are 
available to identify risk factors for and symptoms of perinatal mood disorders.  Two such 
questionnaires are the Antenatal Risk Questionnaire (Johnson et al., 2012) and the Edinburgh 




 Endorsements for perinatal mood screening have increased awareness and discussion 
about perinatal mood disorders.  The American College of Obstetricians and Gynecologists 
released a recommendation in 2015 that women should be screened at least once in the perinatal 
period with a validated screening tool (ACOG, 2015).  ACOG further recommended that 
psychosocial risk factors be assessed once per trimester in pregnancy (Accortt & Wong, 2017).  
In 2016, the US Preventative Task Force (USPTF) recommended screening for depression in the 
general adult population, including pregnant and postpartum women.  Most recently, the USPTF 
drafted a recommendation open for public input, stating “that clinicians provide or refer pregnant 
and postpartum women who are at increased risk of perinatal depression to counseling 
interventions” (2018).  In 2017, the American Medical Association (AMA) adopted a policy 
protocol that included screening for mental health complications in pregnant and postpartum 
women.  All recommendations fail to include more specific guidance regarding the timing of 
screening or tools to be used in such screenings.   
  Practice recommendations in other Westernized countries vary as well.  Australia leads 
other countries with exemplary maternal mental health practices.  As recently as October 2017, 
Australia released national guidelines for the mental health care of perinatal women under the 
Centre of Perinatal Excellence (COPE).  The Expert Working Group, composed of a variety of 
obstetrical, medical, and mental health professionals, reviewed current evidence for perinatal 
mental health screening including several screening questionnaires.  The guidelines included 
evidence-based recommendations as well as consensus-based recommendations, which were 
included in the absence of sufficient quality evidence.  The guidelines recommended screening 
for psychosocial risk factors as early as possible in pregnancy and again postpartum, using the 
ANRQ psychosocial risk assessment tool.  The guidelines endorsed the EPDS as the preferred 
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screening tool for symptoms of perinatal depression and anxiety.  Furthermore, the COPE 
guidelines recommend using the ANRQ in conjunction with the EPDS to screen for both 
psychosocial risk factors and symptoms of perinatal mood and anxiety disorders (2017).   
 In 2016, the Council for Patient Safety in Women's Health Care released a safety bundle 
for maternal mental health.  The bundle outlined four steps for clinicians and healthcare 
organizations to implement optimal maternal mental health practices.  The safety bundle is a 
helpful overview, yet it lacks instruction on which screening tool to use and the timing of that 
assessment.  Kendig et al. (2017) analyzed the steps provided in the safety bundle and suggested 
that mental health assessments of perinatal women include a thorough personal and family 
mental health history, assessment of risk factors, and use of a screening tool for every woman.  
These authors supported the use of the EPDS for symptom identification but lacked 
recommendation of a psychosocial assessment tool.  Despite the various endorsements for 
screening, the US lacks clearly stated guidelines for screening, such as those in Australia.   
Barriers to Screening 
 Barriers are frequently cited as reasons why PMAD screenings are not a routine part of 
prenatal care.  Barriers may include patient, provider, and organizational level obstacles.  Accortt 
and Wong (2017) cited numerous barriers to screening processes and acceptability among 
patients and providers.  These barriers included stigma, lack of education or misinformation 
regarding mental health, cultural differences, fear or reluctance to disclose symptoms, perceived 
lack of time, interest, or qualification on the part of the provider, and previous experiences with 
mental health services.  Provider level barriers included lack of time, inadequate training, lack of 
guidelines, liability concerns, and lack of mental health referral options.  Additional barriers to 
screening included cost, lack of perinatal mental health specialists, wait time for appointments, 
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and lack of resources or knowledge among women about how to seek help (Byatt, Simas, 
Lundquist, Johnson & Ziedonis, 2012).  According to Kingston et al. (2014), “fewer than 20% of 
prenatal care providers assess and treat mental health problems and fewer than 20% of pregnant 
women seek mental health care" (p. 1). 
Screening Questionnaires 
 Accessible questionnaires exist to assess current mental health symptomology as well as 
psychosocial risk factors that increase the risk of peripartum mood disorders.  Validated for use 
in pregnancy and postpartum, the EPDS is available in a multitude of languages, such as 
Spanish, Chinese, and Arabic (Bergink et al, 2011).  The EPDS is a 10- item self-administered 
questionnaire originally designed to identify women with symptoms of postnatal depression 
(Murray & Cox, 1990).  EPDS scores indicating risk vary with a cutoff scores between ten and 
thirteen, or a positive response to self-harm ideation (question 10).  Bergink et al. (2011) 
evaluated the EPDS cutoff for use in pregnancy by trimester, concluding an optimal cutoff of 11 
for the first trimester and 10 for the second and third trimesters.  Most recently, Howard et al. 
(2018) suggested an optimal cutoff score of > 13.  Cutoff at this data point “resulted in weighted 
sensitivity 0.59, specificity 0.94, PPV 0.52, NPV 0.95, likelihood ratio (positive) 9.8, likelihood 
ratio (negative) 0.44” (p. 53).  The Australian guidelines recommended a cutoff score of > 13 
(COPE, 2017).   
  The Patient Health Questionnaire-9 (PHQ-9) is a validated and widely utilized screening 
tool to identify depression in the general population.  The PHQ-9 is commonly used by general 
practitioners.  Similar to the EPDS, the PHQ-9 is a self-administered tool, takes little time to 
complete, assesses self-harm ideation, and is available in many languages.  In an analysis of the 
PHQ-9, Kroenke, Spitzer, and Williams (2001) found good reliability of the tool among 
obstetrical patients; however, the EPDS was more effective in assessing anxiety symptoms in the 
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perinatal population.  Due to the prevalence of anxiety symptoms in perinatal mood disorders, 
the EPDS is the preferable tool for the perinatal population.  Furthermore, the EPDS was 
designed to avoid assessment of symptoms such as energy level, sleep, and appetite changes that 
are indicative of depression, but also common in the peripartum period.  
 The Antenatal Risk Questionnaire (ANRQ) is an English language psychosocial 
assessment tool adapted from the Pregnancy Risk Questionnaire (PRQ) by a group of obstetrical 
and mental health professionals (Johnson et al., 2012).  The ANRQ self-report questionnaire 
evaluates five domains of risk including mental health history, level of practical support and 
emotional support, stressors/losses in the past year, history of physical, emotional, or sexual 
abuse, and levels of anxiety and perfectionism.  Additionally, the tool assesses a woman’s 
perceived level of support from her own mother in childhood.  Austin, Colton, Priest, Reilly, and 
Hadzi-Pavolvic (2013) validated previous studies using a cutoff score of > 23 in both pregnancy 
and postpartum.  The > 23 cutoff score yielded a sensitivity of 0.62 and specificity of 0.64 with a 
positive predictive value of 0.3.  Austin et al. suggested women with a significant mental health 
or abuse history are at greater psychosocial risk regardless of the numeric score.  Despite a rather 
low positive predictive value, the tool allows obstetrical providers to efficiently and quickly 
identify cases that warrant close observation and further assessment.  
Table 1 
Reliability, Validity, Sensitivity and Specificity of Screening Questionnaires 
Tool Evaluation Cut-
off 
Sensitivity Specificity Quality 
































> 23 0.62 0.64 Moderate 
 
Timing of Screening 
 The timing for administration of screening questionnaires to assess risk factors and 
symptomology of peripartum depression is not well-established in the literature.  Based on the 
knowledge that women enter pregnancy with mental health complications or can develop 
symptoms in pregnancy or postpartum, it is logical that screening would occur more than once 
throughout the prenatal and postpartum period.  Caution is necessary when assessing 
symptomology in the first trimester due to somatic and emotional changes associated with early 
pregnancy (Matthey & Ross-Hamid, 2012); thus assessment early in the second trimester is a 
feasible option.  The COPE guidelines (2017) suggested both the EPDS and ANRQ be 
administered “as early as practical in pregnancy” and again between 6 and 12 weeks postpartum. 
The authors also recommended screening be repeated at least once in pregnancy and whenever 
clinically indicated.  Evidence of symptom onset requires screening past the standard 6-week 
postpartum obstetrical appointment. Howard, Mehta, and Powrie (2017) cited a 19.2% 
prevalence for postpartum women to experience a depressive episode within 3 months after birth.  
Due to the prevalence across the perinatal period, the responsibility falls on obstetrical, family 
practice, and pediatric providers to provide maternal mental health screenings.  The American 
Academy of Pediatrics recommends that pediatricians screen mothers for postpartum depression 
at the infant’s 1, 2, and 4-month visits (Earls, 2010).  Biebel, Byatt, Ravech, and Straus (2015) 
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created a toolkit offered by the Massachusetts Child Psychiatry Access Program for pediatric 
providers to screen mothers for postpartum mood complications. 
Effectiveness of Screening 
 Both the EPDS and ANRQ show positive results in identifying women at risk for or with 
symptomology of perinatal mood complications.  Among the most convincing evidence is a 
study by Wisner, Sit and McShea (2013) that examined the onset of symptoms, thoughts of self-
harm, and diagnoses in a large sample of women who screened positive with the EPDS.  
Nineteen percent of the women in the study identified self-harm ideation.  Of the women who 
screened positive in the study, 68.5% went on to have unipolar depression, two-thirds had 
comorbid anxiety disorders, and 22.6% had bipolar diagnoses.  Venkatesh et al. (2016) found 
positive results in screening a large population of 9,000 women.  Among those screened, 
approximately three-fourths of those who scored > 12 on the EPDS went on to be diagnosed with 
major depression and/or anxiety.    
 The ANRQ effectively flags pregnant women with high-risk psychosocial profiles who 
are at higher risk of developing perinatal mental health complications.  Using a cutoff score of   
> 23, Johnson et al. (2012) assessed the ANRQ and found it to be a clinically useful tool in 
guiding identification of psychosocial risk factors associated with an increased likelihood of 
perinatal mood complications.  Ease and speed of use, availability, and satisfaction among 
providers and patients alike, make the ANRQ an appropriate prenatal psychosocial assessment 
tool (Austin et al., 2013).   
Perinatal Mental Illness and Adverse Outcomes 
  Liou, Wang, and Cheng (2016) advised providers to assess pregnant women for 
psychological distress in pregnancy due to the potential adverse health outcomes.  Documented 
pregnancy complications due to anxiety and depression include preterm birth and low birth 
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weight (Liou et al., 2016; Staneva, Bogossian, Pritchard, & Wittkowski, 2015).  Furthermore, 
pregnancy depression disrupts maternal neurocognitive responses, adherence to prenatal 
appointments, pregnancy attachment, and increases the risk of prenatal substance use 
(Letourneau, Dennis, Cosic, & Linder, 2018; Chen & Lin, 2011).  Postpartum mood 
complications increase the risk of decreased maternal-child attachment and interaction, 
potentiating adverse effect on cognitive and socio-emotional development, as well as childhood 
behavioral and developmental problems (Letourneau et al., 2018; Kingston, Tough, & Whitfield, 
2012).  Accortt and Wong (2017) found elevated rates of anxiety disorders in children of mothers 
who experienced perinatal depression that were comparable to rates in children of mothers with 
recurrent depression, suggesting a neurobiological influence.   
 Untreated perinatal mental illness potentially results in chronic maternal mental illness, 
potentiating complications.  Chronic mental illness may create relationship conflicts in the 
family and other social or work relationships (Accortt & Wong, 2017).  Untreated maternal 
mental health complications have implications for the entire family.  Men whose partners suffer 
perinatal mood complications are at greater risk of experiencing their own postpartum mood or 
anxiety disorders further complicating adverse outcomes for the child and the health of the entire 
family.   
 Perinatal suicide and infanticide exist as complications of unrecognized and untreated 
perinatal mental illness.  According to the Marcé Society (2013), “There is a 70 fold increased 
risk of suicide in the first postnatal year after admission for a severe psychiatric episode 
compared to at other times in a woman’s life” (p. 2).  Canadian study examining peripartum 
suicide concluded the average time of antenatal suicide was 5 months gestation while postpartum 
suicide most often occurred at 7.5 months postpartum. The study also recognized the highly 
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lethal means by which peripartum women commit suicide (Thomson & Sharma, 2017).  
Effective identification of perinatal mood and anxiety disorders results in greater likelihood of 
reducing adverse outcomes for mother, child, and family. 
Summary of the Literature 
 The evidence is clear that pregnant and postpartum women are at risk for peripartum 
mood disorders.  Wisner, Sit and McShea (2013) noted a 21.9% prevalence rate of depression 
among women in the first year after birth.  Routine screening of every woman for psychosocial 
risk factors in pregnancy identifies candidates for early psychosocial intervention, which may 
include: social support; financial aid; education regarding newborn care; and spousal or partner 
relationship support.  Additional interventions in pregnancy may also include 
psychopharmacology and psychotherapy.   
 Healthcare providers have numerous opportunities in pregnancy and postpartum to 
identify women at risk for or suffering from this reproductive complication and to intervene 
accordingly.  Screening questionnaires are readily available and have been well- received 
components of care among providers and patients alike.  Screening with the ANRQ and EPDS, 
along with clinical judgment, provides clinicians with an overview of a woman’s psychosocial 
risk and mood symptom evaluation.    
 Recommendations for perinatal mood disorder screening exist among obstetrical, 
midwifery, pediatric, and other medical and public health organizations.  Guidance on how and 
when to screen is limited.  Additionally, numerous patient, provider, and procedural barriers to 
routine screening exist.  As a result of limited direction and perceived barriers to screening, 
perinatal mood disorders remain largely unrecognized and undertreated, resulting in avoidable 
and devastating maternal and child adverse outcomes.  Learman stated, "Screening programs for 
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pregnant and postpartum women reduce the relative risk of continued depression at 3 to 5 
months by 18% to 59% as compared to usual care" (p. 2).  Screening, identification, and 
treatment of perinatal mood and anxiety disorders reduce the risk of chronic symptoms and 
increases the likelihood of wellness in mother and child. 
Project Aims 
 The objective of this project was to decrease provider and organization barriers to 
screening by providing PMAD education and a screening protocol to clinic staff.  The evaluation 
of the project will aim to answer the following three questions: (1) Did the screening protocol 
identify women at risk of PMAD?  (2) Did the use of the screening protocol decrease barriers to 
screening? (3) Did clinic staff find the PMAD screening protocol useful?  
Theoretical Framework 
 The Ottawa Model of Research Use (OMRU) was selected as the guiding theoretical 
framework for the project.  The six key aspects of evaluation in OMRU are practice 
environment, potential adopters, the evidence-based innovation, transfer strategies, adoption, and 
outcomes (Graham & Logan, 2003).   The National Collaboration Centre for Methods and Tools 
(2017) outlined the steps of the OMRU, which was adapted for this project in Figure 1. 
 
Figure 1. Ottawa Model of Research Use  
Assessment
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translation and innovation 
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Evaluation
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the innovation on 
clients/patients, 
practitioners and 
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 The project was a quality improvement project that utilized the framework of the OMRU 
theory.  The first step was an assessment of the practice environment and potential adopters of 
the intervention using a survey via Survey Monkey®.  The second step was the intervention, 
which was the implementation of the screening protocol.  The third step was an evaluation of the 
project aims.  A Survey Monkey® survey was used to determine any decrease in barriers to 
screening and perception of usefulness among clinic staff.  The screening questionnaires were 
used to determine whether the screening protocol identified women at risk of PMAD.   
Screening Protocol 
 The intervention included the implementation of a screening protocol aimed at screening 
for symptoms and risk factors associated with PMAD.  The screening was administered at the 
16-week prenatal appointment.  The screening included a front to back form that included the 
EPDS and ANRQ self-report questionnaires (Appendix 9).  The questionnaires were presented to 
patients, along with written and verbal instructions, at check-in by front office staff.  The 
questionnaires were scored by the medical assistant or nurse.  The provider reviewed the 
questionnaire results with the patient.  Providers made referrals based on questionnaire scores, 
provider judgment, and the screening pathway (Appendix 4, Table 2).  The screening pathway 
was created based on recommended cut-off scores reported in the literature (Bergink et al., 2012; 
Howard et al., 2018; Austin et al, 2013).  ACOG (2015) stated that “systems should be in place 
to ensure follow-up and treatment” (Introduction, para. 5), therefore the screening protocol 
included a resource and referral list for mental health providers, services, and community support 
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agencies.  Additionally, the screening protocol included written patient education to be 
distributed as needed.   
Table 2 
Classification of Risk Based on Screening 
 
Approvals 
 The project proposal was submitted to both the University of Kansas Medical Center 
Institutional Review Board (IRB) and LMH Health IRB for approval.  The project was 
determined to be exempt (Appendix 8).  The EPDS English version is available for use without 
special permission.  Permission was granted by Professor Marie-Paule Austin, developer of the 
ANRQ, to use the ANRQ screening tool for this project (M.P. Austin, personal communication, 




 The setting for this project was Lawrence OB-GYN Specialists (LOGS) is a women’s 
health care clinic owned by LMH Health, a non-profit community-based hospital in Lawrence, 
Kansas.  The clinic employs thirty-seven people, including five physicians, three certified nurse 
midwives, three advanced practice nurses, nurses, medical assistants, ancillary clinic staff, and a 
clinical nurse manager.  As part of the LMH Health organization, LOGS has access to hospital 
support services, such as outpatient social workers.  LMH Health reported 1,052 births in 2017 
(J. Early, personal communication, April 2, 2018).  The author of the project is an employee at 
LMH Health in the Community Outreach and Engagement department.  The author had a prior 
relationship with the clinic staff at LOGS from her prior work as an obstetrical nurse and 
childbirth educator.   
Participants 
 The sample included clinic staff at LOGS, including clinical support specialists, medical 
assistants, nurses, advanced practice registered nurses, certified nurse midwives, and physicians. 
Completed ANRQ and EPDS questionnaires collected during the project period were included in 
the outcome analysis. 
Surveys and Questionnaires 
 Survey Monkey® was used in this project to evaluate the opinions of clinic staff before 
and after the screening protocol intervention.  Clinic staff were emailed a link to access an online 
Survey Monkey® pre- and post-intervention survey.  Each survey was 10-item self-administered 
survey that included multiple choice, yes/no, and free text questions.  The specific questions are 
listed in Appendices 6 and 7.   
 The ANRQ and EPDS questionnaires were administered together.  The questionnaires 
were printed front to back on one sheet of paper and administered at the 16-week prenatal 
appointment (Appendix 9).  The paper with the printed questionnaires also included a text box 
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for providers to free text comments and referral information.  The EPDS questionnaire is a 10-
item self-administered multiple choice questionnaire.  The ANRQ is a self-administered 
questionnaire that includes 9 primary Likert-type questions, 4 subset yes/no questions, and free 
text options.   
Data Collection  
 The pre- and post-surveys were administered via Survey Monkey®.  Three email 
reminders with links to the online survey were sent to the staff for each survey during the 60-day 
collection period.  Individual responses were not tracked as survey responses were anonymous. 
Therefore, those who completed the pre-survey may not have completed the post-survey.  The 
de-identified patient screening questionnaires, the EPDS and the ANRQ, were collected by the 
clinic manager for analysis by the project author.   
Data Analysis 
 Data analyses and data management were performed under the guidance of faculty 
committee members.  Analysis of the data was completed with Excel® and Survey Monkey®.  
Descriptive statistics in the form of response rate percentages represent the results of each pre- 
and post-survey question.  Questions 5, 6, 7, and 8 on the post-survey were intended for clinical 
staff only, who interacted with the patient after the check-in point.  Two of the non-clinical, front 
office, staff responded to these questions, therefore, these two responses were excluded from the 
analysis of questions 5, 6, 7, and 8.   
 The de-identified EPDS and ANRQ questionnaires were analyzed using Excel®.  
Descriptive statistics were used to represent EPDS and ANRQ scores.  The rates of EPDS and 
ANRQ questionnaires were categorized as low, medium or high as indicated by the screening 
protocol criteria (Table 2).  Response rates were determined for each of the ANRQ risk domains 
(mental health history; abuse history; stress/losses in the past year; the level of 
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anxiety/perfectionism; and the lack of partner support).  A scatter plot was used to visualize any 
potential relationship between the EPDS and ANRQ score for each completed screening.  Rates 
of type of referral made after screening were analyzed based on questionnaire free text comments 
from providers.     
Findings 
Demographic Data of Clinic Staff  
 Demographic data collected for the clinic staff included professional role and years 
worked in an obstetrical setting.  The clinic staff respondents included physicians (MD), 
women’s health advanced practice registered nurses (APRN), certified nurse midwives (CNM), 
registered nurses (RN), licensed practical nurses (LPN), medical assistants (MA), clinical 
support specialists, and clinic manager (Figure 2).  A majority of APRN staff, CNM and APRN, 
replied to both the pre- and post-intervention surveys.  Only one physician responded to each 
survey.  There was a decrease in RN response rate from pre- to post-survey.  The majority of 
respondents had worked in an obstetrical setting for more than 5 years (Figure 3).   
 



















Figure 3. Years of Obstetrical Experience 
Clinic Staff Survey Responses 
 Pre-protocol assessment. 
 There was a 73% clinic staff response rate on the pre-protocol survey.  The APRN 
response rate was the highest at 83% and the physician response rate was 20% for the pre-
protocol survey.  All pre-survey respondents agreed that screening for PMAD is an important 
aspect of pregnancy care.  All pre-survey respondents agreed that screening for risk factors of 
PMAD is useful in identifying women at risk for developing PMAD.  The majority (93%) agreed 
that a protocol would be useful in guiding screening practices.   
Provider pre-protocol screening practices were assessed.  All provider respondents 
reported they screened for symptoms of PMAD in their practice.  Half of the provider 
respondents reported routine screening for risk factors associated with PMAD.  Comments 
regarding screening practice are provided in Table 3.  All provider respondents used the EPDS 
questionnaire to screen for symptoms of PMAD in pregnancy. The timeframe of EPDS 








0-5 years 6-10 years 11-15 years 16-20 years 21+ years




screening of risk factors, others discussed personal and family mental health history and support 
system, and some used the Adverse Childhood Experiences (ACEs) questionnaire.  Screening for 
PMAD risk factors varied among providers from no screening, to discussion of personal and 
family mental health history and support system, to use of the Adverse Childhood Experiences 
(ACEs) questionnaire.   
Table 3 










CNM Yes No  “EPDS for all women with hx at intake, 
all women during 2nd trimester, all pp 
women” 
 
“Most” screened for risk factors 
CNM Yes No  “EPDS at 28 weeks, repeated at 2 and 6 
weeks postpartum.” 
 
APRN Yes Yes “EPDS- review with patient and initiate 
discussion based on responses.”  
 
“Discuss hx of mental health dx, FH and 
assess social supports available to pt 
during pregnancy” 
MD Yes Yes “ACOG 16 wks, PP inpatient and 6 wks” 
  
 “ACES, PMH” 
APRN Yes Yes  “EPDS prenatally and in the postnatal 
period” 




 Prior to the protocol implementation, survey respondents reported multiple patient and 
provider barriers to screening. These barriers included time constraints, lack of resource and 
referral options, lack of comfort with the administration of screening questionnaires, a patient's 
willingness to complete the questionnaires, and too many other items to address at the patient 
visit (Figure 4).  Only 11% of the respondents reported: "no perceived barriers" to screening. 
 Post-protocol assessment. 
 There was a 57% clinic staff response rate on the post-protocol survey.  The APRN 
response rate was again the highest at 67% and physician response rate stayed the same at 20% 
in the post- intervention survey.  All post-survey respondents agreed that screening for PMAD is 
an important aspect of pregnancy care.  Following the protocol, 95% of respondents agreed that 
risk factor screening is useful in identifying women at risk for developing PMAD.  The post-
survey assessed the opinion of usefulness of the screening protocol: 73% agreed that the project 
screening protocol was useful in guiding screening practices, 79% agreed that the screening 
protocol was useful in identifying women in need of further psychiatric assessment by a mental 
health provider, and 74% found the protocol useful in identifying women in need of psychosocial 
support referral.  This was a decrease from 93% of pre-survey respondents who responded that a 
protocol would be useful in guiding screening practices 
 The findings revealed a favorable response from providers regarding the usefulness of the 
screening protocol (Table 4).  Additionally, when a woman was identified as medium or high 
risk for developing a PMAD, all provider respondents replied “yes” that the protocol provided 
adequate information for follow up.  The post-protocol survey revealed 100% of the provider 
respondents reported intent to continue the screening protocol as part of their practice.   
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 There was a notable decrease in the majority of perceived barriers to screening following 
the implementation of the screening protocol (Figure 4).  All barriers, except time constraint, 
decreased from the pre-to post-survey assessment.  The largest decreases were seen in the 
patient’s willingness to complete the questionnaires and lack of resources and referral options.  
The number of clinic staff who chose “no perceived barriers” increased from 11% in the pre-
survey to 29% in the post-survey following the implementation of the screening protocol.  The 
barrier of lack of time required to administer the screening tool did not change from pre-to post-
survey.  Additional free text survey comments regarding barriers to screening included: 
“language barriers,” “additional people with patient at the visit,” “forms too busy,” “confusion or 
difficulty with the screening tool format,” and “confusion regarding the timing of the screening.”  
 
Figure 4. Perceived Barriers to Screening 
Table 4 
Provider Opinion of Usefulness of the Screening Protocol  
Question 
Was the protocol . . .  
















Useful in guiding screening 
practices? 
60% 20% 20% 
Useful in identifying women at 
risk of PMAD? 
60% 40%  
Useful in identifying the need for 
further psychiatric assessment? 
50% 50%  
Useful in identifying the need for 
psychosocial support referral? 
60% 40%  
 
 Women Identified at Risk for PMAD 
            EPDS results. 
 The Edinburgh Postnatal Depression Scale (EPDS) was administered to 72 women at the 
clinic during the two month project period, and all of these questionnaires were included in the 
data analysis.  The EPDS scores ranged from a low score of 0 (the lowest possible score on the 
EPDS) to a high score of 18 (the highest possible score is 30).  The mean score was 5, the 
median score was 5, and the mode was 0.  The majority of the patients screened (86%) were 
classified as low risk for developing a PMAD, eight (11%) patients were considered medium 
risk, and two of the patients (3%) met the criteria for high risk for developing a PMAD.  The 
patients that were high risk also had a positive response to question 10, which evaluates suicidal 
ideation and self-harm (Table 2).   
 




Figure 5. Risk Based on EPDS Score 
 ANRQ results. 
 The Antenatal Risk Questionnaire (ANRQ) was administered to 72 women during the 
two month project period.  One respondent did not complete the entire assessment tool, and 
therefore only 71 were analyzed.  The ANRQ scores ranged from 3 (the lowest possible score is 
0) to 53 (the highest score is 60).  The mean score was 15, the median score was 12, and the 
mode was 6.  The majority (72%) of the ANRQ scores indicated low risk as indicated by a score 
< 23 and no significant mental health or abuse history.  However 28% of the ANRQ 
questionnaires indicated risk with scores > 23, and/or a significant mental health history, and/or a 
history of abuse.  Figure 6 summarizes the rates of the five risk domain assessed by the 
questionnaire.  The three highest risk domains were anxiety and perfectionism (31%), stress/loss 
in the previous year (23%), and a history of mental health complications (21%) (Figure 6).  
 
Figure 6. ANRQ Risk Domains 
 Comparing the relationship between EPDS and ANRQ scores. 
 A graph comparison of the EPDS and ANRQ scores is shown in Figure 7.  Two of the 71 
screening assessments revealed high scores on both questionnaires (> 10 for the EPDS and > 23 
ANRQ Risk Domains
Mental Health History (21%)
History of Abuse (16%)
Level of practical support/emotional support from partner (10%)
Stressors/Losses in Last Year (23%)
Anxiety and Perfectionism Levels (31%)
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on the ANRQ), indicating the presence of both symptoms of depression and risk factors.  All 
EPDS questionnaires with scores > 10 corresponded with an ANRQ questionnaire score > 14.  
The majority (75%) of EPDS questionnaires with scores > 10, corresponded with ANRQ 
questionnaires that indicated stress or loss in the previous year and/or high anxiety or 
perfectionism levels.  
     
Figure 7. Paired EPDS and ANRQ Scores 
 Referrals made based on screening pathway. 
 Twenty-six out of 72 screening assessments (corresponding EPDS and/or ANRQ results) 
indicated risk of developing a PMAD based on the screening protocol criteria (Table 4).  Referral 
and free text comments from providers indicated referrals were made most frequently to the 
social worker and mental health providers.  Referrals were also made to the perinatal mental 
health peer support group, Parents as Teachers, Healthy Families Douglas County, and 
Postpartum Support International phone support line (Figure 8).  One referral was made to the 
Willow Domestic Violence Center.  Eight provider free text comments indicated that some 
patients refused a referral or recommended service.  Providers included the following comments 
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Lexapro,” and “pt states she has high anxiety declines referral today,” and “pt states not 
interested in meds or counseling,” and “declines referrals at this time,” and “reviewed results 
with pt and she declines any assistance.”  
 
Figure 8. Referrals  
Discussion 
 An assessment of the clinic staff and clinic environment was the first step in the project.  
The assessment included clinician knowledge of PMAD, screening practice, and clinician 
opinion of screening for PMAD.  The survey respondents overwhelmingly agreed that screening 
for PMAD is an important aspect of pregnancy care and agreed that addressing PMAD decreases 
the likelihood of adverse birth outcomes, postpartum mental health complications, and adverse 
effects in offspring.  These findings were also reflected by the fact that all provider respondents 
reported screening for PMAD symptoms prior to the screening protocol implementation, 
however the provider responses indicated inconsistent screening practices among the provider 
group as a whole.  Only one half of the provider respondents reported screening for risk factors 
associated with PMAD, yet they agreed screening for risk factors was useful in identifying 











women at risk for developing PMAD.  The pre-survey respondents were agreeable to a protocol 
that provided guidance on the screening process.   
 While 100% of the pre-survey respondents agreed a screening protocol would be useful, 
only 73% of the post-survey respondents found this screening protocol useful.  The surveys were 
anonymous and it is unknown whether the exact same clinic staff responded to both the pre- and 
post-surveys. Therefore, it is difficult to draw conclusions about the post survey decrease in 
screening protocol usefulness.  All provider respondents found the protocol useful in identifying 
women at risk of PMAD and in identifying women in need of mental health assessment and/or 
psychosocial support (Table 2).  Providers may have found the protocol more useful than other 
clinic staff.  Providers utilized the screening protocol directly for treatment and referral decisions 
while other clinic staff participated solely in the administration and scoring of the questionnaires.  
Future assessment of a screening protocol might utilize different surveys for the various clinic 
staff roles in order to more accurately assess the opinion of usefulness among clinic staff.  
Additionally, future projects should include a tracking system to pair individual respondents pre- 
and post-protocol survey responses.  A limitation of this project was that it did not track 
individual responses, thus was not able to determine if the same clinic staff responded to both 
surveys and how individual perceptions changed from pre- to post-protocol.  
 Barriers cited in the pre-survey were: time constraints, lack of comfort with the 
administration of screening questionnaires, the perception that patient's aren’t willing to 
complete the questionnaires, the number of items to address at the visit, and lack of resource and 
referral options.  These perceived barriers included patient, provider, and systematic level 
barriers, which was consistent with the barriers listed in the literature (Byatt, Moore Simas, 
Lundquist, Johnson, & Ziedonis, 2012).  The number of respondents who reported no perceived 
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barriers increased from pre- to post-survey.  The most notable decrease was the perception of 
“patient’s willingness to complete the screening questionnaires.”  Byatt et al. (2012) noted a 
provider barrier to screening was “perceived reluctance of their patients to engage in depression 
treatment” (p. 144).  It is reasonable to conclude that a perception of lack of patient engagement 
may include a perceived reluctance on the part of the patient to complete the screening 
questionnaires.  The pre-protocol PMAD and screening education likely contributed to an 
increase in comfort with the administration of the screening questionnaires and an overall 
comfort with the concept of screening for PMAD.  A notable decrease was also seen in the “lack 
of resources and referral options.”  The project resource and referral list likely contributed to the 
reported decrease in perceived lack of referral and treatment resources.   
  The time required to administer the screening questionnaires was identified as a barrier to 
screening in both the pre- and post-survey.  The project screening protocol attempted to address 
this barrier by utilizing appointment wait time to complete the screening questionnaires.  Post-
survey clinic staff comments such as “the form is too busy” and “still feel form is too 
busy/complicated for some” indicated the format may have required clinic staff to spend 
additional time explaining the screening questionnaires.   
  The findings of the project data analysis indicate using the EPDS and ANRQ 
questionnaires together is clinically useful in identifying women at risk of developing PMAD.  A 
total of 26 (36%) screening questionnaires indicated medium or high risk according to the project 
guidelines (Table 2).  Included in the analysis of the EPDS were 8 (11%) questionnaires that 
indicated current symptoms of PMAD.  The ANRQ analysis revealed 20 (28%) questionnaires 
indicated significant risk factors associated with developing a PMAD.  These findings are 
clinically relevant for prenatal care providers.   
33 
 
 A comparison of the corresponding EPDS and ANRQ questionnaires for each patient 
revealed a potential relationship between neuroticism; recent life stress or loss; and mood 
disorder symptoms, which is consistent with the literature.  Howard, Mehta, and Powrie (2017) 
and Meltzer-Brody et al. (2013) cited neuroticism and life stress as risk factors for developing 
PMAD.  In this project, not all the patients who reported high levels of neuroticism had a mental 
health diagnosis or had previously sought care from a mental health provider.  Although 
neuroticism and life stress or loss alone do not represent a significant risk on the ANRQ, the 
findings of this project suggest these items are commonly reported by women who are 
experiencing symptoms of PMAD and should be recognized as self-reported indicators that may 
put a woman at greater risk of PMAD.  The potential relationship between levels of neuroticism 
and perfectionism and risk of developing PMAD warrant future investigation for statistical 
importance. 
  The results of this project found that eight women who were classified as either 
moderate or high risk for developing a PMAD refused services.  Potential reasons women may 
refuse assistance or service may be stigma, fear, a perception that she could work through her 
own problems or use other support options, treatment cost, or previous experiences with mental 
health services (Byatt et al., 2012).  The comments reported by providers in the questionnaires 
were consistent with these possible reasons.  The comments: “pt reports she is doing well on 
Lexapro,” and “pt states she has high anxiety declines referral today,” and “pt states not 
interested in meds or counseling” suggest refusal may be based on perception that current 
support options are sufficient, a perceived ability to work through problems independently, 
and/or barriers to care such as fear, stigma, or cost.  Future assessment of the reason(s) for 
refusal may aid providers in framing conversations with patients to encourage acceptance of 
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follow up services, assessment, and treatment.  Additionally, teaching providers strategies for 
initiating conversations about mental health treatment recommendations and referral for care 
should be considered.  
 Whether a woman receives follow up mental health care after screening depends on 
numerous factors previously discussed, such as availability of services and willingness to receive 
services.  Cox et al. (2017) cited “researchers found that 30% to 50% of women are identified 
with perinatal depression in clinical settings, 14% to 16% receive some treatment, 6% to 9% 
receive adequate treatment, and 3% to 5% experience a remission of symptoms” (p. 1189).  
These findings suggest that without adequate treatment, few women will experience remission of 
mood disorder symptoms.  In this project, the outpatient social worker assisted with on-site 
psychosocial assessment with the at-risk women identified in this project.  It is reasonable to 
consider the addition of integrated mental health services in the obstetrical setting may further 
assist in the identification and treatment of women with PMAD.  Cox et al. (2017) studied the 
integration of a psychiatric mental health nurse practitioner (PMHNP) into an obstetrical and 
gynecological office.  Women who scored > 10 on the EPDS were referred to the PMHNP for 
evaluation.  The addition of a PMHNP increased the number of women referred and evaluated 
within one week of screening by 47%.  The Cox et al. study also found an increase in the 
comfort of providers in assessing patients for PMADs.  Mental health providers integrated into 
the obstetrical office would contribute to the identification and treatment process by providing a 
seamless handoff and onsite mental health support for patients and providers alike.   
Conclusion 
 Mental health complications are prevalent among pregnant and postpartum women.  
Rates of perinatal mental illness do not differ significantly from rates of depression in women 
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across the lifespan.  However, perinatal mood and anxiety disorders are a risk factor for adverse 
health outcomes for a woman, her partner, her developing fetus or child, and the entire family 
system.  Factors that increase the likelihood of developing a PMAD are identifiable.  Screening 
recommendations made by ACOG, USPTF, AMA, and the Council for Patient Safety in 
Women’s Health Care reveal consensus among health organizations that identification of 
perinatal mental illness is essential for maternal and child health.  PMAD screening knowledge 
has not translated into routine practice.  This project created and implemented a PMAD 
screening protocol for an obstetrical clinic.  
 The concept of a screening protocol was well-received by clinic staff.  The barriers to 
screening identified in the pre-protocol assessment were largely overcome.  The clinic staff 
found this screening protocol useful, and the providers found the protocol useful in identifying 
women at risk of a PMAD and women in need of psychiatric assessment and/or psychosocial 
support.  The combined use of the EPDS and ANRQ to assess symptoms of PMAD and risk 
factors associated with PMAD at the 16-week appointment was a clinically significant way of 
identifying risk of PMAD in pregnancy, as evidenced by the 36% of questionnaires representing 
women at risk of developing a PMAD.  The screening protocol was effective in providing 
guidelines for PMAD screening. The protocol also decreased barriers to screening by the 
providers adopting the protocol into practice following the project timeframe.    
 Screening women at the 16-week prenatal appointment for PMAD symptoms and/or 
significant risk factors identifies women at risk of perinatal mood complications and increases 
the likelihood effective treatment in pregnancy.  Screening alone for PMAD is insufficient.  
Follow up resources such as psychiatric assessment, therapeutic interventions, and psychosocial 
support resources are essential to providing effective treatment.  Integrating social workers and 
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mental health providers in the obstetrical setting facilitate the process of psychiatric mental 
health assessment, psychosocial assessment, and support.  Early identification and intervention 
for women at risk for perinatal mental illness increase the likelihood of preventing or lessening a 
perinatal psychiatric complication, thereby improving maternal, infant, paternal, and family 
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Appendix 9: Project Screening Form 
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